Loading…
Does the Multidrug-Resistance Modulator Cyclosporin a Increase the Cardiotoxicity of High-Dose Anthracycline Chemotherapy?
Cyclosporin A has heterogeneous effects on anthracycline-related cardiotoxicity and can prevent multidrug-resistance (MDR). The aim of this study was to explore whether the coadministration of cyclosporin A is accompanied by an increase in cardiotoxicity. Forty-three patients (27 male, 16 female, ag...
Saved in:
| Published in: | Acta oncologica 1997, Vol.36 (7), p.735-740 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c377t-9831b7386424059af528c371da7e15486c4e9105844b5ca790ccec80a65c8f623 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c377t-9831b7386424059af528c371da7e15486c4e9105844b5ca790ccec80a65c8f623 |
| container_end_page | 740 |
| container_issue | 7 |
| container_start_page | 735 |
| container_title | Acta oncologica |
| container_volume | 36 |
| creator | Eising, Ernst G. Gries, Pascal Eggert, Jochen Scheulen, Max E. |
| description | Cyclosporin A has heterogeneous effects on anthracycline-related cardiotoxicity and can prevent multidrug-resistance (MDR). The aim of this study was to explore whether the coadministration of cyclosporin A is accompanied by an increase in cardiotoxicity. Forty-three patients (27 male, 16 female, age: 18-67 yrs (mean: 47.5 yrs, SD: 11.6 yrs)) received 177 radionuclide ventriculography examinations (RNV/177 at rest, 133 at stress) before and during chemotherapy with either doxorubicin (n = 23) or epirubicin (n = 20). RNV studies were applied up to 11 times in the follow-up of the patients. A maximum of 10 courses of chemotherapy was performed. In the doxorubicin group only, the age of the patients and the cumulative dose of the chemotherapeutic agent had a significant negative impact on left ventricular ejection fractions, whereas cyclosporin A had a significant positive influence (multiple analysis of regression, p < 0.05). Cyclosporin A did not cause any significant increase in cardiotoxicity in our patients. |
| doi_str_mv | 10.3109/02841869709001347 |
| format | article |
| fullrecord | <record><control><sourceid>informahealthcare_cross</sourceid><recordid>TN_cdi_crossref_primary_10_3109_02841869709001347</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_3109_02841869709001347</sourcerecordid><originalsourceid>FETCH-LOGICAL-c377t-9831b7386424059af528c371da7e15486c4e9105844b5ca790ccec80a65c8f623</originalsourceid><addsrcrecordid>eNp9kE1LAzEURYMotX78ABfCLNyOJpNkkuBCSv0qKIIouBteM5lOZDopSQasv95oixvBVeDdcx55F6ETgs8pweoCF5IRWSqBFcaEMrGDxqTkJC-K8m0Xjb_zPAFv--gghHeMcUEFH6GRYklQdIw-r50JWWxN9jh00dZ-WOTPJtgQoddp6Oqhg-h8Nl3rzoWV87bPIJv12hsI5secgq-ti-7DahvXmWuye7to82uX8kkfWw86ybZPZGuWLikeVuurI7TXQBfM8fY9RK-3Ny_T-_zh6W42nTzkmgoRcyUpmQsqS1YwzBU0vJApITUIQziTpWZGEcwlY3OuQSistdESQ8m1bMqCHiKy2au9C8Gbplp5uwS_rgiuvmus_tSYnNONsxrmS1P_GtveUn62zSFo6Bqf2rLhFysI5YKphF1uMNs3zi-hNdDFVoM31bsbfJ_O_ucTX58ajaQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Does the Multidrug-Resistance Modulator Cyclosporin a Increase the Cardiotoxicity of High-Dose Anthracycline Chemotherapy?</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Eising, Ernst G. ; Gries, Pascal ; Eggert, Jochen ; Scheulen, Max E.</creator><creatorcontrib>Eising, Ernst G. ; Gries, Pascal ; Eggert, Jochen ; Scheulen, Max E.</creatorcontrib><description>Cyclosporin A has heterogeneous effects on anthracycline-related cardiotoxicity and can prevent multidrug-resistance (MDR). The aim of this study was to explore whether the coadministration of cyclosporin A is accompanied by an increase in cardiotoxicity. Forty-three patients (27 male, 16 female, age: 18-67 yrs (mean: 47.5 yrs, SD: 11.6 yrs)) received 177 radionuclide ventriculography examinations (RNV/177 at rest, 133 at stress) before and during chemotherapy with either doxorubicin (n = 23) or epirubicin (n = 20). RNV studies were applied up to 11 times in the follow-up of the patients. A maximum of 10 courses of chemotherapy was performed. In the doxorubicin group only, the age of the patients and the cumulative dose of the chemotherapeutic agent had a significant negative impact on left ventricular ejection fractions, whereas cyclosporin A had a significant positive influence (multiple analysis of regression, p < 0.05). Cyclosporin A did not cause any significant increase in cardiotoxicity in our patients.</description><identifier>ISSN: 0284-186X</identifier><identifier>EISSN: 1651-226X</identifier><identifier>DOI: 10.3109/02841869709001347</identifier><identifier>PMID: 9490093</identifier><identifier>CODEN: ACTOEL</identifier><language>eng</language><publisher>Basingstoke: Informa UK Ltd</publisher><subject>Adolescent ; Adult ; Aged ; Analysis of Variance ; Animals ; Antibiotics, Antineoplastic - adverse effects ; Antibiotics, Antineoplastic - therapeutic use ; Biological and medical sciences ; Cyclosporine - pharmacology ; Doxorubicin - adverse effects ; Doxorubicin - therapeutic use ; Drug Resistance, Multiple ; Drug Synergism ; Drug toxicity and drugs side effects treatment ; Epirubicin - adverse effects ; Epirubicin - therapeutic use ; Female ; Heart - drug effects ; Humans ; Immunosuppressive Agents - pharmacology ; Male ; Medical sciences ; Middle Aged ; Neoplasms - drug therapy ; Pharmacology. Drug treatments ; Toxicity: cardiovascular system ; Ventricular Function, Left - drug effects</subject><ispartof>Acta oncologica, 1997, Vol.36 (7), p.735-740</ispartof><rights>1997 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 1997</rights><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c377t-9831b7386424059af528c371da7e15486c4e9105844b5ca790ccec80a65c8f623</citedby><cites>FETCH-LOGICAL-c377t-9831b7386424059af528c371da7e15486c4e9105844b5ca790ccec80a65c8f623</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2135749$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9490093$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Eising, Ernst G.</creatorcontrib><creatorcontrib>Gries, Pascal</creatorcontrib><creatorcontrib>Eggert, Jochen</creatorcontrib><creatorcontrib>Scheulen, Max E.</creatorcontrib><title>Does the Multidrug-Resistance Modulator Cyclosporin a Increase the Cardiotoxicity of High-Dose Anthracycline Chemotherapy?</title><title>Acta oncologica</title><addtitle>Acta Oncol</addtitle><description>Cyclosporin A has heterogeneous effects on anthracycline-related cardiotoxicity and can prevent multidrug-resistance (MDR). The aim of this study was to explore whether the coadministration of cyclosporin A is accompanied by an increase in cardiotoxicity. Forty-three patients (27 male, 16 female, age: 18-67 yrs (mean: 47.5 yrs, SD: 11.6 yrs)) received 177 radionuclide ventriculography examinations (RNV/177 at rest, 133 at stress) before and during chemotherapy with either doxorubicin (n = 23) or epirubicin (n = 20). RNV studies were applied up to 11 times in the follow-up of the patients. A maximum of 10 courses of chemotherapy was performed. In the doxorubicin group only, the age of the patients and the cumulative dose of the chemotherapeutic agent had a significant negative impact on left ventricular ejection fractions, whereas cyclosporin A had a significant positive influence (multiple analysis of regression, p < 0.05). Cyclosporin A did not cause any significant increase in cardiotoxicity in our patients.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Analysis of Variance</subject><subject>Animals</subject><subject>Antibiotics, Antineoplastic - adverse effects</subject><subject>Antibiotics, Antineoplastic - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cyclosporine - pharmacology</subject><subject>Doxorubicin - adverse effects</subject><subject>Doxorubicin - therapeutic use</subject><subject>Drug Resistance, Multiple</subject><subject>Drug Synergism</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Epirubicin - adverse effects</subject><subject>Epirubicin - therapeutic use</subject><subject>Female</subject><subject>Heart - drug effects</subject><subject>Humans</subject><subject>Immunosuppressive Agents - pharmacology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasms - drug therapy</subject><subject>Pharmacology. Drug treatments</subject><subject>Toxicity: cardiovascular system</subject><subject>Ventricular Function, Left - drug effects</subject><issn>0284-186X</issn><issn>1651-226X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><recordid>eNp9kE1LAzEURYMotX78ABfCLNyOJpNkkuBCSv0qKIIouBteM5lOZDopSQasv95oixvBVeDdcx55F6ETgs8pweoCF5IRWSqBFcaEMrGDxqTkJC-K8m0Xjb_zPAFv--gghHeMcUEFH6GRYklQdIw-r50JWWxN9jh00dZ-WOTPJtgQoddp6Oqhg-h8Nl3rzoWV87bPIJv12hsI5secgq-ti-7DahvXmWuye7to82uX8kkfWw86ybZPZGuWLikeVuurI7TXQBfM8fY9RK-3Ny_T-_zh6W42nTzkmgoRcyUpmQsqS1YwzBU0vJApITUIQziTpWZGEcwlY3OuQSistdESQ8m1bMqCHiKy2au9C8Gbplp5uwS_rgiuvmus_tSYnNONsxrmS1P_GtveUn62zSFo6Bqf2rLhFysI5YKphF1uMNs3zi-hNdDFVoM31bsbfJ_O_ucTX58ajaQ</recordid><startdate>1997</startdate><enddate>1997</enddate><creator>Eising, Ernst G.</creator><creator>Gries, Pascal</creator><creator>Eggert, Jochen</creator><creator>Scheulen, Max E.</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>1997</creationdate><title>Does the Multidrug-Resistance Modulator Cyclosporin a Increase the Cardiotoxicity of High-Dose Anthracycline Chemotherapy?</title><author>Eising, Ernst G. ; Gries, Pascal ; Eggert, Jochen ; Scheulen, Max E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c377t-9831b7386424059af528c371da7e15486c4e9105844b5ca790ccec80a65c8f623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Analysis of Variance</topic><topic>Animals</topic><topic>Antibiotics, Antineoplastic - adverse effects</topic><topic>Antibiotics, Antineoplastic - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cyclosporine - pharmacology</topic><topic>Doxorubicin - adverse effects</topic><topic>Doxorubicin - therapeutic use</topic><topic>Drug Resistance, Multiple</topic><topic>Drug Synergism</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Epirubicin - adverse effects</topic><topic>Epirubicin - therapeutic use</topic><topic>Female</topic><topic>Heart - drug effects</topic><topic>Humans</topic><topic>Immunosuppressive Agents - pharmacology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasms - drug therapy</topic><topic>Pharmacology. Drug treatments</topic><topic>Toxicity: cardiovascular system</topic><topic>Ventricular Function, Left - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Eising, Ernst G.</creatorcontrib><creatorcontrib>Gries, Pascal</creatorcontrib><creatorcontrib>Eggert, Jochen</creatorcontrib><creatorcontrib>Scheulen, Max E.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Acta oncologica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Eising, Ernst G.</au><au>Gries, Pascal</au><au>Eggert, Jochen</au><au>Scheulen, Max E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Does the Multidrug-Resistance Modulator Cyclosporin a Increase the Cardiotoxicity of High-Dose Anthracycline Chemotherapy?</atitle><jtitle>Acta oncologica</jtitle><addtitle>Acta Oncol</addtitle><date>1997</date><risdate>1997</risdate><volume>36</volume><issue>7</issue><spage>735</spage><epage>740</epage><pages>735-740</pages><issn>0284-186X</issn><eissn>1651-226X</eissn><coden>ACTOEL</coden><abstract>Cyclosporin A has heterogeneous effects on anthracycline-related cardiotoxicity and can prevent multidrug-resistance (MDR). The aim of this study was to explore whether the coadministration of cyclosporin A is accompanied by an increase in cardiotoxicity. Forty-three patients (27 male, 16 female, age: 18-67 yrs (mean: 47.5 yrs, SD: 11.6 yrs)) received 177 radionuclide ventriculography examinations (RNV/177 at rest, 133 at stress) before and during chemotherapy with either doxorubicin (n = 23) or epirubicin (n = 20). RNV studies were applied up to 11 times in the follow-up of the patients. A maximum of 10 courses of chemotherapy was performed. In the doxorubicin group only, the age of the patients and the cumulative dose of the chemotherapeutic agent had a significant negative impact on left ventricular ejection fractions, whereas cyclosporin A had a significant positive influence (multiple analysis of regression, p < 0.05). Cyclosporin A did not cause any significant increase in cardiotoxicity in our patients.</abstract><cop>Basingstoke</cop><pub>Informa UK Ltd</pub><pmid>9490093</pmid><doi>10.3109/02841869709001347</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0284-186X |
| ispartof | Acta oncologica, 1997, Vol.36 (7), p.735-740 |
| issn | 0284-186X 1651-226X |
| language | eng |
| recordid | cdi_crossref_primary_10_3109_02841869709001347 |
| source | Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list) |
| subjects | Adolescent Adult Aged Analysis of Variance Animals Antibiotics, Antineoplastic - adverse effects Antibiotics, Antineoplastic - therapeutic use Biological and medical sciences Cyclosporine - pharmacology Doxorubicin - adverse effects Doxorubicin - therapeutic use Drug Resistance, Multiple Drug Synergism Drug toxicity and drugs side effects treatment Epirubicin - adverse effects Epirubicin - therapeutic use Female Heart - drug effects Humans Immunosuppressive Agents - pharmacology Male Medical sciences Middle Aged Neoplasms - drug therapy Pharmacology. Drug treatments Toxicity: cardiovascular system Ventricular Function, Left - drug effects |
| title | Does the Multidrug-Resistance Modulator Cyclosporin a Increase the Cardiotoxicity of High-Dose Anthracycline Chemotherapy? |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T05%3A07%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-informahealthcare_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Does%20the%20Multidrug-Resistance%20Modulator%20Cyclosporin%20a%20Increase%20the%20Cardiotoxicity%20of%20High-Dose%20Anthracycline%20Chemotherapy?&rft.jtitle=Acta%20oncologica&rft.au=Eising,%20Ernst%20G.&rft.date=1997&rft.volume=36&rft.issue=7&rft.spage=735&rft.epage=740&rft.pages=735-740&rft.issn=0284-186X&rft.eissn=1651-226X&rft.coden=ACTOEL&rft_id=info:doi/10.3109/02841869709001347&rft_dat=%3Cinformahealthcare_cross%3E10_3109_02841869709001347%3C/informahealthcare_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c377t-9831b7386424059af528c371da7e15486c4e9105844b5ca790ccec80a65c8f623%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/9490093&rfr_iscdi=true |